Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Founded in 1995, Depomed has successfully executed on strategy of acquiring, integrating and growing differentiated therapeutic products and building each into a strong market presence. The result is a broad portfolio of pain and neurology specialty pharmaceuticals currently comprised of five FDA-approved products. These include Gralise® for the management of Postherpetic Neuralgia (PHN), Cambia® for the acute treatment of migraine attacks, Zipsor® for the relief of mild to moderate acute pain, Lazanda® for the management of breakthrough pain in cancer patients and our most recent addition, the company’s flagship asset, the NUCYNTA® franchise. Acquired in April 2015 and re-launched in June 2015, the NUCYNTA franchise includes NUCYNTA® ER for the extended management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) and NUCYNTA® for immediate management of moderate to severe acute pain in adults. Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. The company’s Acuform technology is currently being used in four marketed drugs, including Gralise. Depomed’s successful execution on strategy and has resulted in solid product revenue growth over the past three years. Located in Newark, California in the East Bay of San Francisco, Depomed is listed on the NASDAQ market under the ticker DEPO and employs approximately 500 people, of which approximately 350 are part of the Commercial organization.
Company Growth (employees)
Type
Public
HQ
Newark, US
Founded
1995
Size (employees)
490 (est)
Depomed was founded in 1995 and is headquartered in Newark, US

Key People at Depomed

James A. Schoeneck

James A. Schoeneck

President and CEO

Depomed Office Locations

Depomed has an office in Newark
Newark, US (HQ)
300 7999 Gateway Blvd

Depomed Data and Metrics

Depomed Financial Metrics

Depomed's revenue was reported to be $90.4 m in Q1, 2017
USD

Revenue (Q1, 2017)

90.4 m

Gross profit (Q1, 2017)

72.7 m

Gross profit margin (Q1, 2017), %

80%

Net income (Q1, 2017)

(26.7 m)

EBIT (Q1, 2017)

(6.7 m)

Market capitalization (22-Aug-2017)

374.6 m

Cash (31-Mar-2017)

187.8 m
Depomed's current market capitalization is $374.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

134.2 m390.4 m342.7 m455.9 m

Revenue growth, %

191%(12%)33%

Cost of goods sold

7.1 m15.1 m67.9 m87.4 m

Gross profit

127.1 m375.2 m274.8 m368.5 m

Gross profit Margin, %

95%96%80%81%

R&D expense

32.6 m

General and administrative expense

204.5 m

Operating expense total

237.1 m

EBIT

9.3 m236.8 m(50.4 m)24.5 m

EBIT margin, %

7%61%(15%)5%

Interest expense

911 k9.3 m73.4 m83.7 m

Income tax expense

38.7 m

Net Income

43.3 m131.8 m(75.7 m)(88.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

67.7 m51.5 m32.2 m94.5 m104.9 m104.8 m116.7 m110.5 m90.4 m

Cost of goods sold

4.7 m3.5 m3.1 m22.9 m20.9 m23.5 m21 m20.2 m17.8 m

Gross profit

63.1 m48 m29.1 m71.6 m83.9 m81.2 m95.7 m90.3 m72.7 m

Gross profit Margin, %

93%93%90%76%80%78%82%82%80%

R&D expense

5.1 m

General and administrative expense

48.5 m

Operating expense total

53.6 m

EBIT

26.5 m16.7 m(9.8 m)(17.2 m)3.2 m(4.3 m)9.7 m1.3 m(6.7 m)

EBIT margin, %

39%32%(31%)(18%)3%(4%)8%1%(7%)

Interest expense

616 k1.9 m6 m22.1 m22.7 m20.1 m20.3 m20.1 m

Pre tax profit

10.4 m(16.2 m)(18.9 m)

Income tax expense

(4 m)4.2 m17.6 m7.6 m

Net Income

12.7 m6.5 m(11.6 m)(21.7 m)(11.8 m)(20.9 m)(10.5 m)(12.9 m)(26.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

244.7 m488.7 m101.1 m117.7 m

Accounts Receivable

11.5 m27 m71.1 m102.1 m

Inventories

10.1 m8.5 m10.5 m13 m

Current Assets

337 m617.6 m309 m306.2 m

PP&E

8.3 m7.1 m14.8 m15.5 m

Total Assets

508.7 m711.1 m1.4 b1.2 b

Accounts Payable

12.8 m14.9 m

Current Liabilities

156.9 m57.5 m219.6 m227.2 m

Additional Paid-in Capital

347 k76.8 m78.6 m75.9 m

Retained Earnings

(84 m)(116.7 m)

Total Equity

137.4 m364.4 m315.1 m250.8 m

Financial Leverage

3.7 x2 x4.3 x4.9 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

211.1 m546.7 m52.8 m94.1 m107.5 m182 m87.8 m90.4 m187.8 m

Accounts Receivable

17.3 m20 m23.5 m59.8 m68.4 m69.9 m79.5 m87 m67.5 m

Inventories

7.8 m7.3 m6.5 m10.4 m11.4 m10.9 m10.4 m11.3 m12 m

Current Assets

309.6 m632.5 m613.5 m232.2 m302.8 m292.6 m230.2 m260.9 m286.8 m

PP&E

7.7 m7.4 m7.2 m16 m15.4 m15.1 m16.2 m16.1 m15.1 m

Total Assets

458.5 m742.4 m704.4 m1.3 b1.4 b1.3 b1.2 b1.2 b1.2 b

Accounts Payable

44.3 m45.6 m55.8 m113.9 m3.2 m7.4 m11.3 m18.5 m7.2 m

Current Liabilities

114.6 m116 m61.7 m135.7 m180.2 m309.1 m217.9 m216 m301.5 m

Common Stock

246 m252.6 m258.2 m269.9 m277.9 m283.9 m298.1 m

Additional Paid-in Capital

1.9 m75.5 m78 m79.1 m80.8 m78.8 m78.7 m79.2 m75.9 m

Retained Earnings

(53.4 m)(46.9 m)36.1 m14.4 m2.6 m(48.9 m)(59.5 m)(72.4 m)(143.8 m)

Total Equity

179.3 m263.5 m360.1 m346.1 m341.7 m299.7 m297.1 m290.7 m230.2 m

Financial Leverage

2.6 x2.8 x2 x3.8 x4 x4.5 x4.2 x4.3 x5.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

43.3 m131.8 m(75.7 m)(88.7 m)

Depreciation and Amortization

6.2 m12 m85.7 m106.8 m

Accounts Receivable

(7.8 m)(15 m)(44 m)(30.9 m)

Inventories

4.3 m1.7 m9.3 m(3.7 m)

Accounts Payable

16 m(2.7 m)

Cash From Operating Activities

9.8 m(55.9 m)143.9 m65.5 m

Purchases of PP&E

(1.8 m)(599 k)(1.7 m)(2.9 m)

Cash From Investing Activities

(38 m)(47.3 m)(1.1 b)45.5 m

Cash From Financing Activities

243.9 m347.2 m576.6 m(94.4 m)

Interest Paid

39.5 m71.1 m

Income Taxes Paid

45 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

12.7 m6.5 m(11.6 m)(21.7 m)(11.8 m)(20.9 m)(10.5 m)(12.9 m)(26.7 m)

Depreciation and Amortization

2.5 m2.5 m2.5 m26.7 m27 m27 m27 m27 m26.3 m

Accounts Receivable

17.3 m20 m23.5 m59.8 m68.4 m69.9 m79.5 m87 m34.5 m

Inventories

7.8 m7.3 m6.5 m10.4 m11.4 m10.9 m10.4 m11.3 m873 k

Accounts Payable

18.2 m3.2 m7.4 m11.3 m18.5 m(2.4 m)

Cash From Operating Activities

16 m

Purchases of PP&E

(470 k)

Cash From Investing Activities

52.4 m

Cash From Financing Activities

1.7 m

Interest Paid

17.4 m
USDY, 2017

Revenue/Employee

184.6 k

Financial Leverage

5.1 x

Depomed Market Value History

Traffic Overview of Depomed

Depomed Company Life and Culture

You may also be interested in